Bextra (valdecoxib), a new COX-2 inhibitor
January 2002
You'll hear about Bextra (valdecoxib), a new COX-2 inhibitor.
It's being co-marketed now in the U.S. by Pharmacia and Pfizer...the same companies that market Celebrex (celecoxib).
Expect it to be approved in Canada sometime this year.
Practical advice for a better career, with unlimited access to CE
Pharmacy Technician's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote